Sagimet Biosciences, Inc. Class A's total assets for Q3 2025 were $128.40M, a decrease of -6.55% from the previous quarter. SGMT total liabilities were $9.15M for the fiscal quarter, a 26.20% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.